1、个人概况：
刘李，男，博士，副教授，1981年生，药学院药代教研室，2003年中国药科大学药学专业本科毕业，2007年获中国药科大学药物代谢动力学专业硕士学位，2010年获中国药科大学药物代谢动力学专业博士学位，留校工作至今。主要研究方向为药物代谢动力学。教学上主讲本科生《药物代谢动力学》和《临床药物代谢动力学》课程，担任药理学、药代动力学、临床药代动力学实验授课。科研上主持2011年国家自然科学基金青年项目1项（基于胰高血糖素样肽-1释放调控诠释人参二醇型皂苷抗糖尿病作用及其机制，81102503）；参与三项科技部“重大新药创制”（2011ZX09102-009、2011ZX091022-022、2009ZX09501-003）的研究。指导的本科论文一篇获2013年校级本科优秀毕业论文，一篇获2011年江苏省普通高校本专科优秀毕业设计论文优秀指导教师三等奖（排名2）。

2、近年来发表有代表性学术论文
1.GuoH,LiuC,LiJ,ZhangM,HuM,XuP,LiuL*,LiuX*.Amechanisticphysiologicallybasedpharmacokinetic-enzymeturnovermodelinvolvingbothintestineandlivertopredictCYP3Ainduction-mediateddrug-druginteractions.JPharmSci.2013;102(8):2819-36.[Co-correspondingauthor]
2.LiuC,ZhangM,HuMY,GuoHF,LiJ,YuYL,JinS,WangXT,LiuL*,LiuXD*.Increasedglucagon-likepeptide-1secretionmaybeinvolvedinantidiabeticeffectsofginsenosides.JEndocrinol.2013;217(2):185-96.[Co-correspondingauthor]
3.YuY,WangX,LiuC,YaoD,HuM,LiJ,HuN,LiuL*,LiuX*.Combinedcontributionsofover-secretedglucagon-likepeptide1andsuppressedinsulinsecretiontohyperglycemiainducedbygatifloxacininrats.ToxicolApplPharmacol.2013;266(3):375-84.[Co-correspondingauthor]
4.DuanR,HuN,LiuHY,LiJ,GuoHF,LiuC,LiuL*,LiuXD*.BiphasicregulationofP-glycoproteinfunctionandexpressionbyexogenousnitricoxideinCaco-2cells.ActaPharmacolSin.2012;33(6):767-74.[Co-correspondingauthor]
5.LiuL,YuYL,LiuC,WangXT,LiuXD,XieL.Insulindeficiencyinducesabnormalincreaseinintestinaldisaccharidaseactivitiesandexpressionunderdiabeticstates,evidencesfrominvivoandinvitrostudy.BiochemPharmacol.2011;82(12):1963-70.
6.LiuL,PanX,LiuHY,LiuXD,YangHW,XieL,ChengJL,FanHW,XiaoDW.Modulationofpharmacokineticsoftheophyllinebyantofloxacin,anovel8-amino-fluoroquinolone,inhumans.ActaPharmacolSin.2011;32(10):1285-93.
7.LiuL,YuYL,YangJS,LiY,LiuYW,LiangY,LiuXD,XieL,WangGJ.Berberinesuppressesintestinaldisaccharidaseswithbeneficialmetaboliceffectsindiabeticstates,evidencesfrominvivoandinvitrostudy.NaunynSchmiedebergsArchPharmacol.2010;381(4):371-81.
8.LiuL,DengYX,LiangY,PangXY,LiuXD,LiuYW,YangJS,XieL,WangGJ.IncreasedoralAUCofbaicalininstreptozotocin-induceddiabeticratsduetotheincreasedactivityofintestinalβ-glucuronidase.PlantaMed.2010;76(1):70-5.
9.LiuL,DengY,YuS,LuS,XieL,LiuX.Berberineattenuatesintestinaldisaccharidasesinstreptozotocin-induceddiabeticrats.Pharmazie.2008;63(5):384-8.
10.YaoD,LiuL,JinS,LiJ,LiuXD.Overexpressionofmultidrugresistance-associatedprotein2inthebrainofpentylenetetrazole-kindledrats.Neuroscience.2012;227:283-92.[Co-firstauthor]
11.LiuH,LiuL,LiJ,MeiD,DuanR,HuN,GuoH,ZhongZ,LiuX.CombinedContributionsofImpairedHepaticCYP2C11andIntestinalBcrpActivitiesandExpressionstoIncreasedExposureofOralGlibenclamideinStreptozotocin-inducedDiabeticRats.DrugMetabDispos.2012;40(6):1104-12.[Co-firstauthor]
12.LiuL,JuHL,ZhangJ,LiangY,LiuXD,XieL,WangGJ.DevelopmentandvalidationofanLC-MS/MSmethodfordeterminationofvorinostatinbeagledogplasmaanditsapplicationtoapharmacokineticstudy.AsianJPharmacodynPharmacokinet.2010;10(3):209-219.